Table of Contents
- Executive Summary: Key Trends and Market Outlook (2025–2030)
- Technology Primer: How Liposome Systems Cross the Blood-Brain Barrier
- Leading Players and Innovators: Company Profiles and Strategies
- Pipeline Analysis: Clinical Trials and Approved Therapies
- Market Sizing and Forecasts: Growth Projections to 2030
- Regulatory Landscape: Approvals, Challenges, and Opportunities
- Partnerships & Investments: M&A, Venture Funding, and Collaborations
- Overcoming Current Barriers: Scalability, Efficacy, and Safety
- Emerging Applications: Oncology, Neurodegeneration, and Beyond
- Future Outlook: Disruptive Technologies and Next-Gen Delivery Platforms
- Sources & References
Executive Summary: Key Trends and Market Outlook (2025–2030)
The period from 2025 to 2030 is poised to bring significant advancements in blood-brain barrier (BBB) liposome drug delivery systems, reflecting both technological innovation and increased clinical translation. As neurological disorders such as Alzheimer’s disease, brain tumors, and Parkinson’s disease continue to rise globally, the limitations of conventional drug delivery across the BBB have become more pronounced. Liposome-based delivery systems, with their capacity for encapsulating diverse therapeutic agents and enhancing BBB permeation, are gaining momentum as a transformative solution.
One of the key trends for 2025 and beyond is the optimization of liposome surface modification to improve targeting and transport across the BBB. Companies such as Precision NanoSystems are actively developing advanced lipid nanoparticle (LNP) and liposome formulations, focusing on ligand-mediated targeting and functionalization to enhance delivery efficiency to brain tissues. Recent partnerships between pharmaceutical companies and nanotechnology firms underscore the sector’s commitment to accelerating clinical applications of these technologies.
Notably, several biotech firms have entered clinical development stages for liposome-encapsulated drugs aimed at CNS pathologies. For example, Nippon Kayaku has leveraged its liposomal technology platform in oncology, with ongoing efforts to adapt these systems for difficult-to-treat brain cancers. Simultaneously, Evonik Industries has expanded its pharmaceutical services, supporting custom liposome manufacturing and scale-up for BBB applications, which is expected to facilitate more rapid clinical translation and commercial launch of investigational therapies.
The regulatory landscape is also evolving, with agencies such as the U.S. Food and Drug Administration (FDA) providing guidance for nanomedicine-based drug delivery, including liposomal systems. This is expected to streamline approval pathways and encourage further investment in BBB-targeted therapies. Increasingly, contract development and manufacturing organizations (CDMOs) are offering specialized services for liposome formulation, exemplified by Thermo Fisher Scientific (Patheon), enabling biopharma innovators to accelerate product pipelines.
Looking ahead, the outlook for BBB liposome drug delivery systems from 2025 to 2030 is characterized by robust R&D activity, expanding clinical trials, and a supportive regulatory environment. The convergence of innovative formulation technologies, strategic partnerships, and growing demand for CNS therapeutics positions this market segment for strong growth and transformative impact on neurological disease management.
Technology Primer: How Liposome Systems Cross the Blood-Brain Barrier
Liposome-based drug delivery systems have emerged as one of the most promising approaches for overcoming the formidable challenge of the blood-brain barrier (BBB) in central nervous system (CNS) therapeutics. The BBB is a highly selective, semipermeable boundary that restricts the passage of most drugs from the bloodstream into the brain, significantly limiting treatment options for neurological disorders. Liposomes—spherical vesicles composed of lipid bilayers—offer unique advantages for encapsulating, protecting, and transporting therapeutic agents across the BBB.
Recent advances in liposomal engineering have focused on surface modification, targeting ligand attachment, and optimization of lipid composition to enhance BBB penetration. In 2025, several companies are at the forefront of developing liposome formulations specifically designed for brain delivery. For instance, NeuroPharma Labs is working on PEGylated liposomes conjugated with transferrin and other ligands that exploit receptor-mediated transcytosis, thereby facilitating active transport across the BBB. These liposomes can encapsulate small molecules, peptides, or nucleic acids, providing a platform adaptable to various therapeutic payloads.
Another major player, Polaris Lipids, has developed cationic liposome formulations that interact with the negatively charged BBB endothelial membranes, promoting adsorptive-mediated transcytosis. Early-stage clinical data from Polaris Lipids indicate that their platform can deliver up to 15-fold higher concentrations of therapeutic agents into the brain compared to non-modified liposomes, highlighting significant progress in overcoming BBB limitations.
The functionalization of liposomes with antibodies or peptides is an area of rapid development. Creative Biolabs has reported preclinical success with liposomes decorated with anti-transferrin receptor antibodies, which selectively target and cross the BBB while minimizing off-target effects. Their data suggest that these immunoliposomes can achieve targeted delivery and sustained release of drugs within brain tissues.
Looking ahead, the outlook for BBB-penetrating liposome systems is optimistic. The integration of advanced manufacturing techniques, such as microfluidics for precise liposome sizing and drug loading, is expected to further enhance the reproducibility and scalability of these systems. Additionally, regulatory engagement is increasing, with several liposome-based CNS drug candidates entering investigational new drug (IND) phases or early clinical trials as of 2025.
As these technologies mature, experts anticipate that liposome-based BBB delivery platforms will expand the range of treatable CNS conditions and enable more effective therapies for diseases such as glioblastoma, Alzheimer’s, and Parkinson’s. Collaborative efforts between biotech companies and academic research centers are likely to accelerate innovation and translation into clinical practice in the coming years.
Leading Players and Innovators: Company Profiles and Strategies
The landscape of blood-brain barrier (BBB) liposome drug delivery systems is rapidly advancing in 2025, with several leading pharmaceutical and biotechnology companies at the forefront of innovation. These companies are leveraging liposomal technology to enhance central nervous system (CNS) drug delivery, aiming to address the longstanding challenge of traversing the BBB for effective treatment of neurological disorders.
Among the pioneers, Neurodyn Life Sciences has been actively developing liposome-based formulations to improve drug uptake in neurodegenerative conditions. Their pipeline includes candidates designed for Alzheimer’s and Parkinson’s diseases, utilizing proprietary liposomal encapsulation to promote targeted brain delivery while minimizing systemic exposure.
Encapsula NanoSciences is another prominent player, offering custom liposome manufacturing services for both research and clinical applications. In 2025, Encapsula has reported significant collaborations with academic and pharmaceutical partners to create liposomal carriers tailored for BBB penetration, focusing on optimizing particle size, surface charge, and ligand conjugation for receptor-mediated transport.
Lipidor AB, headquartered in Sweden, has expanded its technology platform to include CNS drug delivery. The company is investing in research to modify surface properties of liposomes, such as PEGylation and targeting moieties, in order to enhance BBB transcytosis. Lipidor’s strategic partnerships with neurology-focused biotech firms are expected to yield new clinical candidates entering trials by 2026.
Meanwhile, CordenPharma is supporting the sector as a contract development and manufacturing organization (CDMO), providing GMP-grade liposome production and formulation expertise. The company’s investment in scalable, high-shear homogenization and sterile fill-finish capabilities is enabling pharmaceutical clients to accelerate preclinical and clinical development timelines for BBB-targeting liposomal drugs.
On the innovation front, several companies are exploring active targeting strategies. Creative Biolabs is developing ligand-decorated liposomes engineered for BBB receptor-mediated endocytosis, with a focus on antibodies and peptides that bind to transferrin and insulin receptors expressed on brain endothelial cells. Early preclinical data indicate improved CNS bioavailability for encapsulated therapeutics.
Looking ahead, the competitive landscape is expected to intensify as additional entrants and established pharmaceutical companies invest in proprietary liposome platforms optimized for BBB delivery. Industry collaborations, advances in scalable manufacturing, and ongoing clinical trials will likely define the sector’s trajectory over the next several years, with the potential for the first regulatory approvals of BBB-targeting liposomal drugs by the late 2020s.
Pipeline Analysis: Clinical Trials and Approved Therapies
The development of liposome-based drug delivery systems designed to cross the blood-brain barrier (BBB) is advancing rapidly, with several candidates progressing through clinical pipelines and a few nearing or achieving regulatory approval. As of 2025, the global push to address central nervous system (CNS) disorders—such as glioblastoma, Alzheimer’s disease, and brain metastases—has catalyzed a surge in clinical investigations leveraging liposomal nanocarriers for improved therapeutic delivery to the brain.
One of the prominent platforms in this arena is Arcturus Therapeutics, whose proprietary LUNAR® lipid nanoparticle technology is being adapted for CNS delivery, including preclinical and early-phase clinical trials targeting neurodegenerative disorders. While primarily focused on RNA therapeutics, the company’s advancements in BBB-penetrant formulations are drawing significant attention for their potential to transform treatment paradigms.
Another notable player, Nanospectra Biosciences, is conducting late preclinical and early clinical studies with its AuroShell nanoparticles, which utilize liposome-mimetic structures to facilitate targeted delivery across the BBB. Their focus is primarily on high-grade gliomas, with phase I/II studies underway to evaluate safety and localization within CNS tumors.
In Europe, Polyphor AG is advancing a pipeline candidate, POL7306, a liposomal peptide antibiotic designed for brain infections. The product’s liposomal encapsulation is engineered for enhanced BBB permeability, and phase I safety trials are anticipated to complete enrollment in late 2025.
Meanwhile, Encapsula NanoSciences continues to support academic and industrial partners by providing clinical-grade liposome formulations for investigator-initiated trials. Their technology underpins several ongoing studies investigating chemotherapeutic and anti-inflammatory drugs for brain cancer and neuroinflammation.
On the regulatory front, liposomal doxorubicin formulations, such as those developed by Teva Pharmaceutical Industries Ltd., have established precedents for liposome-based CNS therapies. Although not initially indicated for brain tumors, these products serve as benchmarks for safety and pharmacokinetics, accelerating subsequent approvals for BBB-specific liposomal drugs.
Looking ahead, the outlook for BBB liposome drug delivery systems is robust, with multiple phase II and III trials expected to report data by 2026. Advances in targeting ligands, surface modifications, and scalable manufacturing are set to improve clinical outcomes and regulatory pathways. Collectively, these developments signal a transformative period for CNS drug delivery, potentially leading to the first routine clinical use of BBB-crossing liposomal therapies within the next several years.
Market Sizing and Forecasts: Growth Projections to 2030
The global market for Blood-Brain Barrier (BBB) liposome drug delivery systems is poised for significant growth through 2030, driven by rising investments in central nervous system (CNS) therapeutics, increasing prevalence of neurological disorders, and technological advances in liposomal formulation. As of 2025, the sector is characterized by a mix of early-stage clinical programs and a few advanced candidates nearing pivotal trials, with regulatory frameworks evolving to accommodate novel nanomedicine platforms.
Key industry players are advancing proprietary liposome technologies designed to enhance therapeutic delivery across the BBB. Precision NanoSystems is developing customizable lipid nanoparticle (LNP) platforms, supporting pharmaceutical companies in optimizing CNS-targeted drug delivery. In parallel, Evotec SE has entered collaborations with major pharma partners to deploy its integrated discovery and development capabilities for BBB-penetrant formulations, with a focus on neurodegenerative diseases.
Recent announcements from Encapsula NanoSciences signal commercial readiness for cGMP-grade liposome manufacturing, supporting both preclinical and clinical development pipelines for CNS applications. The company reports increased demand for customized liposomal systems specifically engineered for BBB penetration, reflecting broader industry trends toward precision targeting and reduced systemic toxicity.
Looking ahead, the market is expected to accelerate as several clinical-stage programs progress toward regulatory submissions by 2027–2028. The U.S. FDA and EMA have issued draft guidances that clarify requirements for nanomedicine characterization and quality, streamlining the path for new entrants. Additionally, public-private partnerships—such as the ongoing initiatives facilitated by The International Nanomedicine Society—are fostering precompetitive research and harmonizing standards across jurisdictions.
- By 2025, the BBB liposome drug delivery sector is estimated to be in a high-growth phase, with annualized market growth rates expected to exceed 15% over the next five years, contingent on clinical and regulatory milestones.
- Expansion is anticipated across both pharmaceutical and contract development manufacturing organizations (CDMOs), driven by the need for scalable, compliant liposome production capabilities.
- Therapeutic focus areas include glioblastoma, Alzheimer’s disease, Parkinson’s disease, and rare pediatric CNS disorders, where unmet need and commercial opportunity are greatest.
- Strategic alliances and licensing deals are expected to proliferate, as companies seek to access proprietary BBB-penetrant liposome technologies and accelerate late-stage clinical development.
In summary, the BBB liposome drug delivery market is set for robust expansion through 2030, shaped by scientific advances, maturing clinical pipelines, and an increasingly supportive regulatory environment. Continued collaboration between technology providers, pharmaceutical sponsors, and regulatory agencies will be crucial for realizing the full therapeutic and commercial potential of these innovative delivery systems.
Regulatory Landscape: Approvals, Challenges, and Opportunities
The regulatory landscape for blood-brain barrier (BBB) liposome drug delivery systems is rapidly evolving, reflecting both the promise of this technology and the unique challenges it presents. As of 2025, regulatory agencies worldwide are increasingly engaging with industry and academia to adapt guidelines that account for the distinct properties of nanocarriers such as liposomes, particularly when intended to traverse the BBB for the treatment of central nervous system (CNS) disorders.
In the United States, the U.S. Food and Drug Administration (FDA) has expanded its focus on nanotechnology-enabled drug delivery. The FDA’s Nanotechnology Regulatory Science Research Plan outlines specific considerations for the characterization, safety, and efficacy assessment of liposomal formulations, with additional scrutiny when these carriers are designed for BBB penetration. Several investigational new drug (IND) applications for liposome-based therapies targeting CNS diseases have been submitted in recent years, with increased interaction between sponsors and FDA scientists during the pre-IND phase. As of 2025, no BBB-targeted liposomal therapy has received full FDA approval, but multiple candidates are in late-stage clinical trials.
In Europe, the European Medicines Agency (EMA) has similarly prioritized guidance for nanomedicines, including a reflection paper on the data requirements for liposomal products. The EMA’s Innovation Task Force continues to collaborate with developers to clarify the regulatory path, especially for products utilizing novel targeting ligands or surface modifications to enhance BBB transport.
Key regulatory challenges remain. The heterogeneity of the BBB in health and disease complicates the demonstration of therapeutic consistency and safety. Regulatory bodies require robust data on biodistribution, potential off-target effects, immunogenicity, and long-term fate of liposomal carriers. Manufacturers such as Pfizer Inc. and The Liposome Company, Inc. are working closely with agencies to address these challenges, leveraging advanced imaging and biomarker strategies to support their submissions.
Opportunities are emerging as regulators increasingly recognize the unmet medical need in CNS disorders and the limitations of conventional therapies. The FDA and EMA have both indicated willingness to consider accelerated pathways—including Breakthrough Therapy and Priority Medicines (PRIME) designations—for BBB-targeted therapies that demonstrate compelling early evidence of efficacy. Additionally, collaborative initiatives such as the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network are supporting preclinical and translational development, with a focus on regulatory science to streamline future approvals.
Over the next few years, the regulatory environment is expected to further mature, with dedicated guidance documents and the first potential approvals anticipated for BBB liposome drug delivery platforms, particularly for rare or intractable CNS diseases. Ongoing dialogue between developers, regulators, and patient groups will be essential to ensure that the promise of these innovative systems is realized while maintaining rigorous safety standards.
Partnerships & Investments: M&A, Venture Funding, and Collaborations
The landscape of blood-brain barrier (BBB) liposome drug delivery systems is marked by dynamic partnerships, strategic investments, and mergers and acquisitions (M&A) that are shaping the future of central nervous system (CNS) therapeutics in 2025 and the coming years. As the need to effectively deliver drugs across the BBB intensifies—particularly for neurodegenerative diseases and brain tumors—industry players are leveraging collaborations to accelerate innovation and clinical translation.
- Strategic Collaborations: In 2025, a significant trend is the deepening of public-private partnerships to advance BBB-penetrant liposomal platforms. For example, Evotec SE continues its collaborative research programs with academic and biopharmaceutical partners to discover and optimize lipid nanoparticle technologies for CNS drug delivery, building on its prior relationships with major pharmaceutical companies.
- Venture Funding: Targeted investments are fueling the pipeline of BBB-focused liposome technologies. Sagent Pharmaceuticals and Genentech have both participated in recent venture rounds supporting startups developing liposome formulations capable of enhanced BBB penetration. These investments are aimed at expanding preclinical and early clinical programs, with a particular focus on rare CNS disorders and glioblastoma.
- Mergers & Acquisitions: The sector has witnessed consolidations, with established drug delivery companies acquiring innovative startups to integrate proprietary BBB liposomal technologies. For instance, Boehringer Ingelheim completed the acquisition of select assets from a neuro-focused biotech specializing in targeted liposome carriers, aiming to bolster its CNS pipeline.
- Consortia and Multi-party Initiatives: Global consortia such as the Innovative Medicines Initiative (IMI) are facilitating multi-stakeholder collaborations, bringing together industry, academia, and regulatory bodies to standardize and validate liposome-based BBB delivery platforms. These efforts are expected to streamline the path toward clinical trials and regulatory approval.
- Outlook: Over the next few years, the sector is expected to see increased cross-border collaborations, with Asian pharmaceutical companies (such as Takeda Pharmaceutical Company Limited) expressing interest in joint ventures aimed at co-developing advanced BBB-targeted liposomal therapeutics. Capital inflows from strategic and venture investors will likely continue, focused on companies demonstrating robust translational data and scalable manufacturing capabilities.
These partnership and investment activities are poised to accelerate the clinical translation of BBB liposome drug delivery systems, addressing long-standing challenges in CNS therapeutics and opening new commercial and therapeutic opportunities by 2025 and beyond.
Overcoming Current Barriers: Scalability, Efficacy, and Safety
Blood-brain barrier (BBB) liposome drug delivery systems are at the forefront of neurological disease therapeutics, but their clinical translation hinges on overcoming major challenges in scalability, efficacy, and safety. In 2025, efforts are intensifying to address these barriers as several industry leaders and research-driven companies move candidates toward later-stage development and potential commercialization.
Scalability remains a critical hurdle, as reproducible, high-throughput manufacturing of liposomal formulations with consistent size and loading characteristics is essential for regulatory approval. Companies such as Evonik Industries AG and Polaris Lipids are investing in modular, automated production lines and advanced lipid nanoparticle (LNP) technologies, leveraging microfluidic and continuous flow systems to enable batch-to-batch consistency. These approaches are designed to meet the anticipated demand for CNS-targeted therapeutics, with scalability pathways that align with FDA and EMA guidelines for Good Manufacturing Practice (GMP).
Efficacy in BBB liposome delivery has been driven by surface engineering strategies. In 2025, companies like Creative Biolabs and Precision NanoSystems are advancing ligand-targeted liposomes that exploit receptor-mediated transcytosis, such as transferrin and insulin receptors, to enhance brain uptake. Early data from preclinical and first-in-human studies show improved delivery of small molecules and biologics across the BBB, with several investigational new drug (IND) applications underway for Alzheimer’s disease, glioblastoma, and lysosomal storage disorders.
Safety is paramount, as the immune system can recognize and clear nanoparticle-based carriers, while off-target effects may induce neuroinflammation or systemic toxicity. Companies such as Abbott Laboratories are evaluating PEGylation and biomimetic coating methods to prolong circulation time and reduce immunogenicity. Recent safety studies, including those disclosed by Pfizer for their lipid nanoparticle platforms, have demonstrated reduced cytokine release and minimal neurotoxicity in animal models, with plans for expanded safety profiling in human subjects expected in the next two years.
Looking forward, the outlook for BBB liposome drug delivery systems in 2025 and beyond is increasingly optimistic. Regulatory engagement is intensifying, with collaborative frameworks emerging between manufacturers and agencies to define standards for characterization, release testing, and long-term pharmacovigilance. Industry consortia, such as those led by International Pharmaceutical Federation (FIP), are supporting harmonization efforts and best practices for CNS nanoparticle therapeutics. As these multidimensional challenges are systematically addressed, the clinical and commercial potential of BBB liposome drug delivery systems is expected to accelerate, with the first wave of approved therapies likely to emerge within the next several years.
Emerging Applications: Oncology, Neurodegeneration, and Beyond
The blood-brain barrier (BBB) remains a formidable obstacle for central nervous system (CNS) therapeutics, particularly in oncology and neurodegenerative disease treatment. Liposome-based drug delivery systems—engineered nanocarriers capable of encapsulating both hydrophilic and hydrophobic drugs—are at the forefront of innovation in overcoming the BBB. As of 2025, clinical and industry momentum is accelerating, propelled by advances in liposome design, surface modification, and payload optimization.
In oncology, liposomal formulations are enabling targeted delivery of chemotherapeutics to brain tumors, reducing systemic toxicity and improving efficacy. Companies such as LipoCure have advanced liposomal platforms that demonstrate increased accumulation of drugs like doxorubicin in glioblastoma models, leveraging surface ligands to enhance BBB penetration. Pfizer, with its legacy in liposomal doxorubicin (Doxil), is exploring next-generation liposome modifications to augment CNS drug delivery for both primary and metastatic brain cancers.
In neurodegeneration, the pipeline is expanding for diseases such as Alzheimer’s and Parkinson’s. Nanomi is developing micro- and nanoliposome carriers for sustained release of neuroprotective agents, aiming to address the challenge of maintaining therapeutic concentrations in the brain. The company’s modular platform allows for conjugation with targeting moieties (e.g., transferrin, peptides), facilitating receptor-mediated transcytosis across the BBB.
Preclinical data from Creative Biolabs highlight the potential of stealth liposomes—coated with polyethylene glycol (PEG)—to evade immune detection and prolong circulation, critical for CNS targeting. These stealth systems are being evaluated for delivery of anti-amyloid and anti-synuclein antibodies, providing hope for disease-modifying therapies in Alzheimer’s and Parkinson’s.
Beyond traditional CNS diseases, liposome drug delivery systems are being studied for rare lysosomal storage disorders, epilepsy, and even psychiatric conditions. The trend toward personalized medicine is evident, with Precision NanoSystems developing customizable liposomal platforms for patient-specific drug combinations and genetic payloads.
Looking ahead, significant growth is anticipated in the field as regulatory guidelines for nanomedicine mature and more liposome-based therapeutics enter clinical trials. Collaboration between biotech innovators and established pharmaceutical manufacturers is expected to accelerate translation from bench to bedside, heralding a new era in the treatment of CNS disorders through advanced BBB-penetrating liposome technologies.
Future Outlook: Disruptive Technologies and Next-Gen Delivery Platforms
The landscape of blood-brain barrier (BBB) liposome drug delivery systems is poised for significant transformation in 2025 and the coming years, driven by disruptive technologies and next-generation delivery platforms. Liposomes, as biocompatible nanocarriers, are at the forefront of efforts to overcome the restrictive nature of the BBB and enable targeted therapy for central nervous system (CNS) disorders. The key trends shaping the sector involve both technological innovation and strategic collaborations between biotech companies and academic institutions.
A major advance is the engineering of ligand-targeted liposomes, which can selectively bind to BBB transporters or receptors, enhancing CNS uptake of encapsulated therapeutics. Companies such as Precision NanoSystems are developing lipid nanoparticle platforms that can be customized for enhanced BBB penetration, leveraging surface modifications and conjugation techniques to improve specificity and efficiency. Similarly, Creative Biolabs is actively expanding its portfolio of functionalized liposomes, focusing on receptor-mediated transcytosis strategies to achieve higher delivery rates to brain tissue.
Clinical translation is accelerating, with several investigational new drug (IND) applications and early-phase trials anticipated in 2025. For example, Avanti Polar Lipids, a subsidiary of Croda, is collaborating with pharmaceutical partners to supply high-purity lipids for preclinical and clinical studies of BBB-penetrating formulations. Concurrently, Evonik Industries is scaling up cGMP manufacturing capabilities for liposomal products designed to treat neurodegenerative diseases, indicating a readiness for larger-scale clinical deployment.
The integration of advanced manufacturing technologies, such as microfluidics and continuous processing, is anticipated to further streamline production, reduce variability, and enable more precise control over liposome size and drug loading—factors critical for BBB transit efficacy. Particle Works is among the companies investing in automated systems for reproducible, scalable liposome production tailored for neurological applications.
Looking ahead, the convergence of artificial intelligence (AI) and data-driven design is set to accelerate the optimization of liposome characteristics for BBB delivery. AI-driven screening of lipid compositions and surface ligands, as pursued by technology partners of Thermo Fisher Scientific, is expected to shorten development timelines and enhance translational success.
Overall, 2025 will mark a pivotal year for BBB liposome drug delivery, with disruptive advances likely to unlock new therapeutic options for conditions such as glioblastoma, Alzheimer’s disease, and Parkinson’s disease. The sector’s growth will hinge on continued cross-sector partnerships, regulatory engagement, and investment in scalable, GMP-ready manufacturing platforms.
Sources & References
- Nippon Kayaku
- Evonik Industries
- Thermo Fisher Scientific (Patheon)
- Encapsula NanoSciences
- Lipidor AB
- CordenPharma
- Nanospectra Biosciences
- Polyphor AG
- Evotec SE
- European Medicines Agency
- National Institutes of Health
- Boehringer Ingelheim
- Innovative Medicines Initiative (IMI)
- Takeda Pharmaceutical Company Limited
- LipoCure
- Nanomi
- Thermo Fisher Scientific